Brief: Pharmather Announces Assigned FDA Approval Goal Date Of Its Priority Original Abbreviated New Drug Application For Ketamine
10/05/2024 13:38
May 10 (Reuters) - Pharmather Holdings Ltd PHRM.CD :
* PHARMATHER ANNOUNCES ASSIGNED FDA APPROVAL GOAL DATE OF
ITS
PRIORITY ORIGINAL ABBREVIATED NEW DRUG APPLICATION FOR KETAMINE
* PHARMATHER HOLDINGS LTD - RECEIPT OF AMENDMENT
ACKNOWLEDGMENT
LETTER FOR ITS PRIORITY ORIGINAL ABBREVIATED NEW DRUG
APPLICATION FOR KETAMINE
* PHARMATHER HOLDINGS LTD - GENERIC DRUG USER FEE AMENDMENTS
OF
2022 GOAL DATE OF OCTOBER 29, 2024
Source text for Eikon: ID:nGNX23CPnn
Further company coverage: PHRM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application